AKT Pathway Phosphorylation Antibody Array
Akt signaling is an important transduction pathway that plays a critical role in controlling the balance between cell survival and apoptosis. Several Akt substrate proteins have been identified, few have been implicated in the genesis or progression of melanoma. Akt activation is initiated when the translocated Akt is phosphorylated on T308 residue by phosphoinositide-dependent kinase-1. When the second phosphorylation site S473 is phosphorylated by rapamycin-insensitive mTORC2, complete activation is achieved. Prior phosphorylation of Y315 and Y326 residues is a pre-requisite for the activation of Akt kinases. Activated Akt phosphorylates GSK3α/β, PRAS40, NFκB and many other proteins. The AKT signaling network plays a major functional role in cells that are often dysregulated in vascular abnormalities, including endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and macrophages.
Fig.1 AKT signaling network targets and regulates critical cellular substrates.1
Improved understanding of the molecular wiring of the AKT signaling network continues to make an impact that cuts across most disciplines of biomedical sciences. Creative Biolabs developed AKT signaling pathway phosphorylation screening service with antibody array, which consists of 137 phospho-specific antibodies and more than 130 phosphorylation sites involved in AKT signaling pathways can be tested.
Related Signaling Pathway
- AKT signaling pathway
Antibody Array Targets
| Targets |
| 4E-BP1 (T36) | c-Jun (T239) | IRS-1 (S307) | p53 (S6) |
| 4E-BP1 (T45) | c-Jun (T91) | IRS-1 (S312) | p53 (S9) |
| AFX (S197) | c-Jun (T93) | IRS-1 (S636) | p53 (T18) |
| Akt (S473) | c-Jun (Y170) | IRS-1 (S639) | S6K1 (S424) |
| Akt (T308) | c-Kit (Y721) | JAK1 (Y1022) | S6K1 (S411) |
| Akt2 (S474) | elF4E (S209) | JAK2 (Y1007) | Paxillin (Y118) |
| ASK1 (S83) | FAK (Y861) | JAK2 (Y221) | Paxillin (Y31) |
| ASK1 (S966) | FAK (Y925) | Met (Y1234) | PDK1 (S241) |
| BAD (S112) | FKHR (S256) | Met (Y1349) | PTEN (S370) |
| BAD (S136) | FKHR (S319) | p21Cip1 (T145) | PTEN (S380) |
| BAD (S155) | FKHRL1 (S253) | p27Kip1 (S10) | PTEN (S380/T382/T383) |
| BCL-2 (S70) | Gab1 (Y627) | p27Kip1 (T187) | Pyk2 (Y402) |
| BCL-2 (T56) | GSK3A (S21) | p53 (S15) | Raf1 (S259) |
| BCL-XL (S62) | GSK3B (S9) | p53 (S315) | Raf1 (S338) |
| c-Jun (S243) | NFKBIA (S32/S36) | p53 (S33) | rpS6 (S235) |
| c-Jun (S63) | NFKBIA (Y42) | p53 (S37) | Zap-70 (Y319) |
| c-Jun (S73) | CHUK (T23) | p53 (S46) | Zap-70 (Y493) |
Protocol Outline
- Extracted protein and biotinylated
- Blocked antibody array
- Incubate with treated protein and control
- Incubate with streptavidin-conjugated fluorophore
- Scan with a microarray laser scanner
- Perform densitometry and analysis
Our Analysis Service
- Suitable for protein, cell and tissue samples from human, mouse and rat
- 6×107 cells or 150 µg protein
- Set replicate spots: treated sample and control
- Results are delivered in 4-5 weeks
For more detailed information about our antibody arrays, please feel free to contact us.
Reference
-
Glaviano, Antonino, et al. "PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer." Molecular cancer 22.1 (2023): 138.
Distributed under Open Access license CC BY 4.0, without modification.